anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to medicine and specifically to gastroenterology, and is concerned with fasting-diet therapy. A saline laxative is administered to the patient and food intake is ceased. Beginning the first day of fasting, 1.5-2 liters of purified water are introduced daily in equal portions, and at the end of the day a cleansing enema is given consisting of 1.5-2 liters of purified water having 10 drops of colloidal silver per 1 liter. A psychotherapeutic conversation is held every day, as well as walks of 30-40 minutes 2-3 times per day and gymnastics according to the Japanese system of Nishi. Beginning the second day of fasting, over the course of 16 days, every day at 7:30 the patient is administered 1/3 of a teaspoon of plant organic sorbent in a glass of water, which, a half-hour later, is followed by drinking a glass of water. At 9:30 and 18:30, anthelmintic plant preparation is administered, and at 9:40 and 18:40, 1 capsule of the plant preparation &#34;Catrel&#34; is administered. 1 teaspoon of colloidal silver is administered at both 10:00 and before bed, it is held in the mouth for 6 minutes and then swallowed, and one drop of same is also administered to each of the eyes and the nose.
The invention comprises steroids of the formulae &lt;FORM:1029919/C2/1&gt; (wherein R1 is H or C1-5 alkyl, R2 is a C1-5 aliphatic hydrocarbon group and R3 is H or Me) and acid-addition salts thereof.  They may be prepared by reacting the corresponding 2-hydroxymethyl-3-keto-androstanes with hydrazines R1NHNH2.  Products wherein R1 is hydrogen may be N-alkylated to give a mixture of isomers of the above general formulae. Examples are given. The steroids of the invention are anabolics and they may be made up into pharmaceutical or veterinary compositions with suitable carriers. These may take the form of tablets, dragees, ointments, creams, solutions, suspensions or emulsions and may contain preservers, stabilizers, wetting agents, emulsifiers, salts for regulating the osmotic pressure or buffers.
PURPOSE:To obtain a whitening cosmetic containing a whey mineral consisting essentially of an unabsorbing fraction obtained by subjecting a whey to treatment with an ion exchange resin and/or its treated material, having excellent effect and free from trouble due to cosmetic and being safe. CONSTITUTION:Cheese whey and other whey are, as necessary after adjusting pH of the whey, treated with an ion exchange resin (especially preferably carboxymethylcellulose-based or sulfopropyl-cellulose-based ion exchange resin). An unabsorbing fraction obtained by this treatment is concentrated and cooled to crystallize lactose and the crystallized lactose is removed to afford whey mineral. Further, lactose in this whey mineral is partially removed from this whey mineral or a polymer material having &gt;=100000 molecular weight is removed from this whey mineral to give a whey mineral treated material. At least one kind of mineral selected from a group of minerals obtained by this method is included to provide the objective whitening cosmetic. This cosmetic effectively utilizes a tyrosinase inhibitor contained in milk and a physiologically active substance contained in a polymer fraction.
PURPOSE:To obtain the titled composition useful as a feed additive or animal drug having improved palatability, economically in high quality without using an organic solvent, by removing microbial cells from fermentation culture liquid of a depsipeptide antibiotic substance and concentrating the liquid with a reverse-osmosis membrane. CONSTITUTION:Microbial cells are removed from a fermentation culture liquid of a depsipeptide antibiotic substance (e.g. neoviridogrisein, griseoviridin, etc.) and the treated liquid is concentrated with a reverse-osmosis membrane. The material and module of the reverse-osmosis membrane is selected according to the composition of the fermentation culture liquid, etc. In the case of a neoviridogrisen fermentation culture liquid, a spiral reverse-osmosis membrane made of cellulose acetate is preferable. The concentrated liquid is adjusted to &lt;=6pH to precipitate the titled composition. The composition has improved palatability compared with conventional product.
An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab&#39;, (Fab&#39;) 2 , CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.
PURPOSE:To produce an antiurokinase antibody, by cultivating a hybridized cell of murine B cells and myelomatous cells in a culture medium containing peptone obtained by the enzymic decomposition of animal meat, transferrin and bovine blood serum in a low concentration of the blood serum. CONSTITUTION:B cells, e.g. murine B cells, are subjected to the plasmogamy with myelomatous cells, e.g. murine myelomatous cells, by the well-known method to give a hybridized cell capable of producing an antibody, which is then cultivated in a culture medium obtained by adding 0.5-10mg/ml peptone prepared by the enzymic decomposition of animal meat, 0.4-250mug/ml transferring and 0.1% (V/V) or more bovine blood serum to the well-known basic culture medium, e.g. NO.199 or Ham&#39;s F-10 culture medium, at 6-8 pH and 25-40 deg.C. The produced antibody is then recovered from the culture fluid separated from the cells by the conventional method.
PURPOSE: To obtain a promoter containing, as active ingredient, an alkyl glyceryl ether, high in safety to the skin and capable of promoting the percutaneous absorbability of the active ingredient. CONSTITUTION: This promoter contains, as active ingredient, 0.01-90wt.% of a compound of the formula (R is a 8-36C alkyl or alkenyl; X&lt;1&gt; and X&lt;2&gt; are each H or a residue resulted by removing one OH group from pentaerythritol, one or both of them being such residues). This promoter is obtained by appropriately mixing a percutaneous absorbent with a medicinal ingredient used in conventional skin preparations for external use such as analgesic/anti-inflammatory agents, hormone preparations, antimycotic agents and vitamin preparations followed by formulating the mixture in a base pref. such as a cream preparation, ointment preparation, gel preparation, lotion preparation, emulsion, or adhesive tape preparation. The medicinal ingredient to be used is 0.001-50 pts.wt. per pt.wt. of the promotor.  Even lower concentrations of the medicinal ingredient have pharmacological effect comparable to the case with conventional products, thus reducing the side effects of the medicinal ingredient.
The utility model relates to a tablet printed with dose dividing markers. The number of the dose dividing marker which is printed on the surface of one side of the tablet is &gt;=1 so that the whole tablet is divided into at least two equal parts. The number of the dose dividing marker which is printed on the surface of the other side of the tablet is &gt;=0 so that the whole tablet is divided into at least zero equal part. The tablet can be in shapes of circle, ring, rectangle, square, trapezoid, ellipse, capsule, triangle and regular polygon. The whole tablet can be taken by adults, and is particularly suitable for special patients such as children, the old and patients suffering from liver and kidney dysfunction due to the facts that doses of the tablet can be conveniently and quickly adjusted through the dose dividing markers printed on the surface of the tablet, deficiency of dose specifications of the tablets in the market can be made up and adverse drug reaction caused by inaccurate doses can be lessened. The tablet printed with the dose dividing markers is simple in structure, and the dose dividing markers can be printed on the surface of the tablet by the aid of existing tablet printing machines, so that cost is reduced, marking dies are not needed to purchase and a shortcoming that the marking dies are easily to be worn is avoided.
PURPOSE: To control microorganism in an aqueous system such as an aqueous coating material, cosmetics, a liquid for metal processing by adding 3, 5- dimethyl-1-hydroxymethylpyrazole, etc. CONSTITUTION: This control of microorganism in an aqueous system is performed by adding 0.1-1,000 pts.wt. compound of the formula (R and R&#39; is H or CH2 ; R&#34; is H, a halogen or nitro) or its hydrochloric acid salt based on 1,000,000 pts.wt. aqueous system. The aqueous system is exemplified by an aqueous coating material such as an acrylic emulsion, a solution for adhesion, a lustering agenl, a solution for a metal processing, a sealant product, chemicals for papermaking, a disperser for a pigment, a starch slurry and cosmetics. The reduction of viscosity, gas-formation, unpleasant smell, reduction of pH, destruction of emulsion, discoloring, gelaticon, etc., are prevented by the control method.
A method and system for implementing an on-line pharmacy website that allows customers of a particular pharmacy company to order new prescriptions, refill prescriptions and transfer existing prescription. The method and system also afford a user access to personal information such as their prescription history. Integration of an internet server hosting the website with a pharmacy company&#39;s intranet server and customer database allows a customer full on-line access to their information stored by the pharmacy company, as well as access to drug information. A further feature includes allowing the user to format and print their prescription history and records. Another feature of the system and method includes a “click-free” registration of customers with the website by entry of customer data by company personnel at any company location connected to the intranet server, such as at a pharmacy store. Personnel solicit information from the customer including, for example, an e-mail address. Registration of the customer is then performed by the company personnel and website access information is, in turn, communicated to the customer via e-mail.
PURPOSE: To obtain a hair tonic having excellent hair-nourishing activity to various alopecia independent of symptom or individual difference by including a glyceryl etherified polyhydric alcohol. CONSTITUTION: This hair tonic contains a compound expressed by formula I (R&lt;1&gt; is a 6-22C alkyl, an alkenyl or an alkoxyalkyl; R&lt;2&gt; is H or expressed by formula II) in an amount of 0.0001-20wt.%, preferably 0.01-10wt.% as an active component. Otherwise, the hair tonic may be jointly used with a hematogenic accelerator, an antibacterial agent, a cuticle-dissolving agent, an anti-seborrhea agent, a local stimulating agent, an anti-inflammatory agent, a humectant, an anti-androgenic hormone agent or a hair follicle activator, etc., in an amount of 0.001-5wt.% for enhancing the hair-nourishing effect. Furthermore, the objective cosmetic is suitably mixed with an additive used in an usual cosmetic and mainly prepared in a formulation of lotion. A formulation of cream or gel is also possible. A liquid agent is preferably mixed with a carbon dioxide gas and adjusted to pH4.5-6.5.
&lt;P&gt;PROBLEM TO BE SOLVED: To find an effective component utilized for a food and a health food or the like, from a horse chestnut seed coat of a so-called food remainder part which is not served for usual eating.  &lt;P&gt;SOLUTION: A polyphenol is obtained by extracting the horse chestnut seed coat of an object to be wasted, by means of hot water treatment, alkaline solution immersion treatment, and boiling with an alkaline solution or the like. The polyphenol has a structure of flavan-3-ol as a basic structure. It is guessed that the basic structure is related to an interflavan bonding and is polymerized. The polymerized polyphenol has antioxidizing action and oxygen inhibition action or the like and is added to the food of the health food or the like.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain an anti-inflammatory drug useful for preventing and treating skin diseases, having excellent safety and utility free from irritation and hormone-like side effects, containing a sialic acid and a sialic acid derivative as an active ingredient. CONSTITUTION:One or a combination of two or more selected from the group consisting of a sialic acid (e.g., N-acetvlneuraminic acid) and a sialic acid derivative (e.g., sialic acid bonded oligosaccharide) is used and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The amount of the substance is 0.0001-50wt.% based on sum of the composition. An external preparation is produced in the dosage form of powder, granule, bulky powder, capsule, syrup, suppository or injection. A dose by internal use and percutaneous administration is 0.001-2.000mg based on 1kg weight daily and administered dividedly 1- several times. Sialic acid and the sialic acid derivative is obtained by extraction from cow&#39;s milk, goat milk or human milk.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for a drug which repairs myocardial tissues by allowing an effective amount of G-CSF or EPO to act on the ischemic myocardial part in order to bring about the myocardial tissue repairing and regenerating capability possessed by G-CSF and EPO without side effects to a maximum.  &lt;P&gt;SOLUTION: The intravenously administering pharmaceutical composition for treating myocardial infarction includes a liposome having an average particle diameter of ≥70 and ≤150 nm whose surface has a sialyl Lewis X tetrasaccharide chain (Neu5Ac. alpha. 2-3 Gal. beta. 1-4 (Fuc. alpha. 1-3) GlcNAc) and erythropoietin and/or granulocyte colony-stimulating factor which is included in the liposome and is intravenously administered.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present invention provides a new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, or medication for its innocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of athylakoid extract in the making of an oral composition for treating preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orality administering an effective dose of a thylakoid extact. Further is provided an oral composition comprising a thylakoid extract and a vehicle for oral ingestion or oral administration. An oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consists of water, physiological saline or propylene glycol is also provided as food or a food supplement, or as a peliet, or encapsulated granules or powder. The carrier may be present in an amount of 0.01% to 95% (w/w) of the total composition. The purified thylakoids are present in an amount which achieves a dosage of 0.1 to 10 mg per Kg of a subject&#39;s body weight.
PROBLEM TO BE SOLVED: To obtain a serum having a metastasis-controlling action and useful as a metastasis-controlling agent by administering a specific compound to an animal and subsequently collecting blood from the animal. SOLUTION: This serum is obtained by forcibly orally administering a compound of the formula (R&lt;1&gt; is a 1-6C alkyl; R&lt;2&gt; is a 1-10C alkyl, a 3-7C cycloalkyl, etc.; A is CH2 CH2 , CH=CH, etc.; X is O, NH) to a mammalian at a daily dose of 0.0001-80mg/kg everyday for 6-60 days, collecting blood from the mammalian 24hr later after the final administration, subjecting the blood to a centrifugal treatment, and subsequently collecting the serum from the supernatant. A fraction having a mol.wt. of 10000-50000 in the serum has the metastasis- controlling action and is useful, but the active ingredient is unstable to heat and is inactivated, when heated at a temperature of &gt;=60 deg.C for 30min. A metastasis-controlling agent containing the serum as an active ingredient is used by an oral administration method, etc.
FIELD: medicine, pharmacy technology. SUBSTANCE: tablets have 10-80% &#34;Mesna&#34; as biologically active substance and the following components, weight part per 1 weight part &#34;Mesna&#34;: binding agent 0.01-1; raising agent 0.03-0.4; agent promoting smooth surface formation 0.01-0.2, filling agent 0.1-1 and, additionally, standard physiologically inert carbonated mixture in the case of carbonated tablets making 0.05-30. Granulate has the same components at indicated amounts, except for raising agent. Method of tablet making involves &#34;Mesna&#34; granulation with C 1 -C 4 -alcohol or acetone or with mixture of these solvents with water and with special additions: filling agent, binding agent or raising agent. Total amount or part of special additions is added and other part - after granulation. Granulate is dried and slipping. taste, sweetening and aromatic substances were added. Mixture is homogenized and pressed. Granulate is obtained by the same described granulating stage from granulate components. Granulate is dried, slipping agent is added and covered with film shell, then taste, sweetening and aromatic substances were added and homogenized. Granulate and tablets can be covered with acceptable polymeric shell. EFFECT: improved method of producing. 10 cl
PURPOSE:To obtain an emulsifying/solubilizing agent having excellent hydrophilic nature and safty and being stable for heat and light by composing essentially of an ester of maltotriitol and a higher fatty acid. CONSTITUTION:An emulsifying/solubilizing agent is composed essentially of an ester obtained from maltotriitol having &gt;=70% purity and a higher fatty acid. Surface-active agents having a wide range from high HLB to low HLB whose hydrophilic natures are high and low respectively can be obtained by adjusting the degree of esterification in a process. The agents having 4-19 HLB and the degree of esterification from mono-ester to hexa-ester are obtained. The emulsifying/solubilizing agent has an extremely high hydrophilic nature and excellent solubility in water. The agent is stable for heat and light and the browning isn&#39;t caused even if it is used for emulsification at a high temperature. Furthermore, its toxicity is very low and is extremely safe as a surface-active agent used for human body.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely ophthalmology, and can be used for prevention of choroidal neovascularisation following cataract phacoemulsification. After sampling the patients to be involved in the offered therapy, the cataract phacoemulsification surgery follows by a standard technique. A flexible intraocular lens is implanted. After the intraocular lens implanted, lucentis is injected intravitreally. ^ EFFECT: method provides prevention of choroidal neovascularisation and thereby a macular oedema following the cataract phacoemulsification surgery in the patients with age-related macular dystrophy and confluent drusen of Bruch&#39;s membranes. ^ 1 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a food material having a high antiobestic effect or blood cholesterol level elevation inhibiting activity, and to provide a food and drink containing the food material.  &lt;P&gt;SOLUTION: This invention comprises the antiobestic agent comprising a component contained in cassis fruits as an active component. The invention comprises the food and drink comprising the component contained in the cassis fruits and having antiobestic activity and indicating that the component is used for suppressing or prophylaxis of obesity. The invention comprises a blood cholesterol level elevation inhibitor using the component contained in the cassis fruits as the active component. The invention compres the food and drink containing the component contained in the cassis fruits and having suppressing effect on the total blood cholesterol level and indicating that the content is used for suppressing the total cholesterol level.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing an extract of Acanthopanax senticosus Harms whereby foreign matters can be efficiently removed and drug efficacy components can be effectively purified; and an extract of Acanthopanax senticosus Harms from which a product containing drug efficacy components in a high content can be easily produced.  &lt;P&gt;SOLUTION: The extract of Acanthopanax senticosus Harms contains drug efficacy components, i.e., eleutherosides E and B represented by formulas 1 and 2 (wherein Me is methyl; and R is glucosyl), the sum of contents (dry basis) of these components being 4 wt.% or higher, preferably 10 wt.% or higher. This extract is produced by extracting Acanthopanax senticosus Harms with a hydrophilic solvent and subjecting the resultant extracted solution to adsorption with a hydrophobic adsorbent followed by purification by desorption with an organic solvent. Preferably, the purification is conducted after a hydrophobic component in the extracted solution is transferred into a hydrophobic organic solvent to be removed from the solution. Preferably, the hydrophobic organic solvent is water-saturated butanol or ethyl acetate. Preferably, the foregoing organic solvent is ethanol or water-containing ethanol.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The prepn. of aq. solns. of potentiated sulphonamides, based on a cpd. of formula R1CH(R)2 (I)(R1 is H or organic gp.; R is an antibacterially effective sulphonamide bonded via the amino gp.) and a sulphonamide potentiator, and the dry residue of such solns. comprises (a) dissolving (I) and a sulphonamide potentiator in an inert aprotic org. solvent and then removing the solvent and the residue dissolved in water contg. a base in an amt. equimolar to the sulphonamide, or alternatively (a&#39;) dissolving (I), a sulphonamide potentiator and opt. a sulphonamide salt corresp. to (I) and the equiv. amt. of a base in water, and (b) evaporation to provide dry residues.